Active Pancreatic Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Pancreatic Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Pancreatic Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Pancreatic Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Pancreatic Cancer Clinical Trial FAQ

Are there clinical trials for pancreatic cancer with KRAS mutations?

Yes — KRAS inhibitors are one of the most exciting recent developments in pancreatic cancer research. Since over 90% of pancreatic ductal adenocarcinomas (PDAC) carry a KRAS mutation, novel KRAS inhibitors (targeting G12D, G12V, and pan-KRAS) are in active clinical trials. Your oncologist can request molecular profiling to confirm which KRAS mutation you carry.

Can pancreatic cancer patients join trials after surgery (adjuvant)?

Yes. There are adjuvant trials for patients who have had surgery (a Whipple procedure or distal pancreatectomy) and are now in the recovery phase. These trials test whether adding a new agent after standard chemotherapy can reduce the risk of the cancer returning. Eligibility usually requires surgery within a specific time window and adequate recovery.

Is immunotherapy effective for pancreatic cancer?

Standard checkpoint immunotherapy has had limited success in most pancreatic cancers because the tumor microenvironment suppresses immune activity. However, the small subset (~1–2%) with MSI-H/dMMR pancreatic cancer responds well. Current trials are testing novel strategies to overcome immunosuppression — including combination approaches, cancer vaccines, and CAR-T therapies — specifically designed for pancreatic cancer.

Does my performance status affect whether I can join a pancreatic cancer trial?

Yes. Most trials require patients to have an ECOG performance status of 0 or 1 (meaning you can carry out light daily activities independently). Some trials accept ECOG 2. Pancreatic cancer can affect nutritional status and energy levels, so if you have concerns about your performance status, discuss this with your oncologist before applying to a trial.

How do I find a pancreatic cancer trial if there are no major cancer centers near me?

Many pancreatic cancer trials have sites at community cancer centers, not just academic medical centers. Trialify sorts trial sites by distance from your ZIP code. Some trials also offer remote consent and telehealth eligibility visits, reducing the number of in-person trips needed. Your oncologist can also contact a trial site on your behalf.

Explore Other Cancer Trial Guides

• Stage 4 Pancreatic Cancer — Stage 4 (metastatic) pancreatic cancer is the most advanced form of the disease, with cancer spread to the liver, lungs, or other organs. Trials are urgently needed and actively recruiting for KRAS inhibitors, cancer vaccines (mRNA-based), antibody-drug conjugates, and novel immunotherapy strategies for PDAC.
• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.
• Liver Cancer — Liver cancer trials are studying checkpoint inhibitor combinations, locoregional treatments (TACE, ablation), and novel targeted agents for hepatocellular carcinoma across all disease stages.
• Ovarian Cancer — Ovarian cancer trials are investigating PARP inhibitor combinations, antibody-drug conjugates, folate receptor-targeted therapy, and immunotherapy — with studies available for both platinum-sensitive and resistant disease.